TFP5, a peptide derived from p35, a Cdk5 neuronal activator, rescues cortical neurons from glucose toxicity

Journal of Alzheimer's Disease

Volumn 39, Issue 4, 2014, Pages 899-909

  Bk, Binukumar ^a   Zheng, Ya Li ^a,b   Shukla, Varsha ^a   Amin, Niranjana D ^a   Grant, Philip ^a   Pant, Harish C ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Ningxia People's Hospital   (China)

Author keywords

Alzheimer's disease; cyclin dependent kinase 5; diabetes; neuroinflammation; oxidative stress

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GLUCOSE; GLUTATHIONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEPTIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P35; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TAU PROTEIN; TFP5 PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BRAIN CELL; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; ENZYME ACTIVITY; EXPERIMENTAL HYPERACTIVITY; FETUS; IN VITRO STUDY; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; UPREGULATION;

ALZHEIMER'S DISEASE; CYCLIN DEPENDENT KINASE 5; DIABETES; NEUROINFLAMMATION; OXIDATIVE STRESS;

AMINO ACID SEQUENCE; ANIMALS; CEREBRAL CORTEX; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; GLUCOSE; MOLECULAR SEQUENCE DATA; NEURONS; PEPTIDE FRAGMENTS; PHOSPHOTRANSFERASES; RATS;

EID: 84896881584     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131784     Document Type: Article

References (37)

1. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: Prevalence estimates using the 2000 census. Arch Neurol 60, 1119-1122.
2. Feldman EL (2003) Oxidative stress and diabetic neuropathy: A new understanding of an old problem. J Clin Invest 111, 431-433.
3. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53, 1937-1942.
4. Peila R, Rodriguez BL, Launer LJ (2002) Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 51, 1256-1262.
5. Biessels GJ, Kappelle LJ (2005) Increased riskof Alzheimer's disease in Type II diabetes: Insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 33, 1041-1044.
6. Cox DJ, Kovatchev BP, Gonder-Frederick LA, Summers KH, McCall A (2005) Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 28, 71-77.
7. Brands AM, Biessels GJ, de Haan EH, Kappelle LJ (2005) The effects of type 1 diabetes on cognitive performance: A meta-analysis. Diabetes Care 28, 726-735.
8. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481.
9. Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490, 115-125.
10. Tomlinson DR, Gardiner NJ (2008) Glucose neurotoxicity. Nat Rev Neurosci 9, 36-45.
11. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820.
12. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404, 787-790.
13. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107, 1058-1070.
14. Zheng YL, Hu YF, Zhang A, Wang W, Li B (2010) Over-expression of p35 in Min6 pancreatic beta cells induces a stressed neuron-like apoptosis. J Neurol Sci 299, 101-107.
15. Patrick, GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622.
16. Cruz JC, Tsai LH (2004) Cdk5 deregulation in the pathogen-esis of Alzheimer's disease. Trends Mol Med 10, 452-458.
17. Meijer L, Kim SH (1997) Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol 283, 113-128.
18. Zheng, YL, Kesavapany S, Gravell M, Hamilton, RS, Schubert M, Pant HC (2005) A Cdk5 inhibitory peptide reduces tau hyperphosphorylation and apoptosis in neurons. EMBO J 24, 209-220.
19. Zheng YL, Amin ND, Hu YF, Rudrabhatla P, Shukla V, Pant HC (2010) A 24-residue peptide (p5), derived from p35, the Cdk5 neuronal activator, specifically inhibits Cdk5-p25 hyperactivity and tau hyperphosphorylation. J Biol Chem285, 34202-34212.
20. Zheng YL, Li BS, Amin ND, Albers W, Pant HC (2002) A peptide derived from cyclin-dependent kinase activator (p35) specifically inhibits Cdk5 activity and phosphorylation of tau protein in transfected cells. Eur J Biochem 269, 4427-4434.
21. Shukla V, Zheng YL, Mishra SK, Amin ND, Steiner J, Pant HC (2013) A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer's disease phenotypes in model mice. FASEB J 27, 174-186.
22. Veeranna, Amin ND, Ahn NG, Jaffe H, Winters CA, Pant HC (1998) Mitogen-activated protein kinases (Erk1, 2) phosphorylateLys-Ser-Pro (KSP) repeats in neurofilament proteinsNF-H and NF-M. J Neurosci 18, 4008-4021.
23. Kesavapany S, Amin N, Zheng YL, Nijhara R, Jaffe H, Pant HC (2004) p35/cyclin-dependent kinase 5 phosphorylation of ras guanine nucleotide releasing factor 2 (RasGRF2) mediates Rac-dependent extracellular signal-regulated kinase 1/2 activity, altering RasGRF2 and microtubule- associated protein 1b distribution in neurons. J Neurosci 24, 4421-4431.
24. Bitel CL, Kasinathan C, Kaswala RH, Klein WL, Frederikse PH (2012) Amyloid-fj and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J Alzheimers Dis 32, 291-305.
25. Ubeda M, Kemp DM, Habener JF (2004) Glucose-induced expression of the cyclin-dependentprotein kinase 5 activator p35 involved in Alzheimer's disease regulates insulin gene transcription in pancreatic beta-cells. Endocrinology 145, 3023-3031.
26. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918-934.
27. Kawamori D, Kajimoto Y, Kaneto H, Umayahara Y, Fujitani Y, Miyatsuka T, Watada H, Leibiger IB, Yamasaki Y, Hori M (2003) Oxidative stress induces nucleo-cytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun NH(2)-terminal kinase. Diabetes 52, 2896-2904.
28. Harmon JS, Stein R, Robertson RP (2005) Oxidative stress-mediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J Biol Chem 280, 11107-11113.
29. Strocchi P, Pession A, Dozza B (2003) Up-regulation of cDK5/p35 by oxidative stress in human neuroblastoma IMR-32 cells. J Cell Biochem 88, 758-765.
30. Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A (2011) High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: Inflammatory pathway inhibition. Diabetes 60, 1090-1099.
31. Quan Y, Jiang CT, Xue B, Zhu SG, Wang X (2011) High glucose stimulates TNFa and MCP-1 expression in rat microglia via ROS and NF-/cB pathways. Acta Pharmacol Sin 32, 188-193.
32. Wang J, Li G, Wang Z, Zhang X, Yao L (2012) High glucose-induced expression of inflammatory cytokines and reactive oxygen species in cultured astrocytes. Neuroscience 202, 58-68.
33. Navarro-Gonzalez JF, Mora-Fernandez C (2008) The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19, 433-442.
34. Chen J, Cui X, Zacharek A, Cui Y, Roberts C (2011) White matter damage and the effect of matrix metalloproteinases in type 2 diabetic mice after stroke. Stroke 42, 445-452.
35. Llewelyn JG (2003) The diabetic neuropathies: Types, diagnosis and management. J Neurol Neurosurg Psychiatry 74, ii15-ii19.
36. Muyllaert D, Terwel D, Kremer A, Sennvik K, Borgh-graef P (2008) Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: A model for hippocampal sclerosis and neocortical degeneration. Am J Pathol 172, 470-485.
37. Sundaram JR, Chan ES, Poore CP, Pareek TK, Cheong WF, Kesavapany S (2012) Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. JNeurosci32, 1020-1034.